Marshall Wace LLP lessened its stake in shares of Icon Plc (NASDAQ:ICLR) by 78.0% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 11,071 shares of the medical research company’s stock after selling 39,147 shares during the quarter. Marshall Wace LLP’s holdings in Icon were worth $1,512,000 at the end of the most recent reporting period.
A number of other hedge funds also recently bought and sold shares of the business. Systematic Financial Management LP grew its holdings in shares of Icon by 8.1% during the first quarter. Systematic Financial Management LP now owns 10,042 shares of the medical research company’s stock worth $1,372,000 after purchasing an additional 755 shares in the last quarter. Norges Bank purchased a new position in shares of Icon during the fourth quarter worth about $84,127,000. OLD National Bancorp IN grew its holdings in shares of Icon by 44.3% during the first quarter. OLD National Bancorp IN now owns 4,059 shares of the medical research company’s stock worth $554,000 after purchasing an additional 1,247 shares in the last quarter. HighPoint Advisor Group LLC purchased a new position in shares of Icon during the first quarter worth about $218,000. Finally, Xact Kapitalforvaltning AB purchased a new position in shares of Icon during the first quarter worth about $601,000. 85.74% of the stock is owned by institutional investors and hedge funds.
Shares of NASDAQ:ICLR traded up $1.95 during midday trading on Thursday, reaching $152.64. 220,511 shares of the company’s stock traded hands, compared to its average volume of 282,637. The company has a market capitalization of $8.10 billion, a P/E ratio of 24.27, a price-to-earnings-growth ratio of 2.06 and a beta of 0.56. The company has a current ratio of 2.02, a quick ratio of 2.02 and a debt-to-equity ratio of 0.30. Icon Plc has a one year low of $118.10 and a one year high of $156.34. The stock’s 50 day moving average price is $147.69.
ICLR has been the subject of a number of recent research reports. Wolfe Research initiated coverage on Iqvia in a research report on Tuesday, April 2nd. They issued a “market perform” rating for the company. BidaskClub downgraded Amyris from a “hold” rating to a “sell” rating in a research report on Thursday, June 27th. Mizuho boosted their target price on Icon from $154.00 to $160.00 and gave the stock a “buy” rating in a research report on Tuesday, June 11th. Barclays set a $24.00 target price on Tenet Healthcare and gave the stock a “hold” rating in a research report on Wednesday, April 17th. Finally, ValuEngine upgraded Yirendai from a “strong sell” rating to a “sell” rating in a research report on Friday, May 3rd. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and eight have given a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $156.63.
Icon Company Profile
ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.
Featured Article: What is Blockchain?
Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.